Apoliktos neo concept -
A personalized therapy in 3 to 7 days
Preinception-stage biotech in immuno-oncology with an international team of experts and founders aiming to develop personalized therapeutics against multiple myeloma and Seed raising of $10M.
In Apoliktos, we are working on a novel neo concept against cancer. We aspire to help develop a personalized therapy for patients in 3 to 7 days.
First, with the help of the physician, we would evolve the diagnostic and perform a patient stratification.
Then, we would be able to develop a personalized patient approach using tumor-mutation binders combined with the immunotherapy that would improve dramatically the approach. This combination would happen right at the bedside.
Finally, the patient would receive a heavily personalized immuno-therapy treatment.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.AcceptRefusePrivacy policy